Comments
Request technical outlook (one year-plus) for Hindustan Unilever and Colgate-Palmolive.
Panini Deshpande
Hindustan Unilever (₹572.6): Ever since bottoming out from the 2004 low of ₹104, Hindustan Unilever has been on a long-term uptrend forming higher peaks and troughs. This long-term uptrend will stay in place as long as the stock trades above ₹400-410 base zone. It has the possibility of reaching the target of ₹650 and ₹725 in the long-term.
Medium-term trend has been down since registering a new peak at ₹725 in August 2013. The stock’s key long-term support at ₹550 provided the base by arresting its downtrend this January and again in early March.
The stock is attempting to reverse higher from this support. A rally above the immediate resistance level at ₹600 will pave way for an up move to ₹650 in the medium-term. Key supports to watch are positioned at ₹550 and ₹515. The short-term trend is sideways between ₹550 and ₹600.
Colgate-Palmolive India (₹1,345.7): Colgate-Palmolive too is in a long-term uptrend, rising almost four-fold from its 2008 levels to the 2013 peak at ₹1,580. However, since then the stock has been very volatile.
The long-term uptrend will be in motion as long as the stock trades above the significant range of ₹960 and ₹1,000. An emphatic move above ₹1,400 will strengthen the uptrend and take the stock northwards to ₹1,500 or even to ₹1,580 in the long-term. Key long-term supports to keep note of are at ₹1,200 and then at ₹1,100 levels. The stock has been on a modest uptrend from the last August low of ₹1,190. But now the stock is testing resistance at ₹1,365. A break past this hurdle will push the stock higher to ₹1,400 initially and ₹1,450 in the medium-term. Immediate supports are at ₹1,300, ₹1,250 and ₹1,200.
Kindly review the long-term outlook on the stocks of L&T and GSK Pharma.
Pandurang
Larsen & Toubro (₹1,219.5): When L&T decisively broke through its key resistance at ₹1,150 in early March, its long-term trend has turned bullish from sideways. Investors with a long-term perspective can consider holding the stock with a stop-loss at ₹950. The long as well as medium-term outlook is bullish. The stock can trend to ₹1,300 in the medium-term. Strong move above ₹1,300 can accelerate the stock to ₹1,400 and ₹1,450 in the long-term.
The stock is currently testing a key resistance at ₹1,250. A breach of this can take the stock to ₹1,300 in the short- to medium-term. On the other hand, a fall below ₹1,100 will pose a threat to the short-term uptrend and the stock can decline to ₹1,030 and to ₹1,000 in the medium-term.
Direct supports are at ₹1,200 and ₹1150.
GlaxoSmithKline Pharmaceuticals (₹2,592.3): Since 2008, the stock has been on a long-term uptrend. It encountered resistance at ₹3,050 in February and has plunged 15 per cent so for this month, raising questions about the sustainability of the uptrend. However, investors with a long-term horizon can hold the stock with a stop-loss at ₹1,900.
An upward reversal from the significant support at ₹2,300 can take the stock higher to ₹2,700 or ₹2,800 in the long-term. But the short-term trend is down for the stock. A fall below ₹2,450 will reinforce bearish momentum and pull the stock down to ₹2,350 or ₹2,300.
Traders with short-term perspective should go long only if the stock advances above ₹2,650 levels, for a target of ₹2,800.
I purchased shares of NTPC at ₹135. Please let me know the prospects.
N Raman
NTPC (₹114.4): The stock has been on a long-term downtrend from its January 2010 peak at ₹239, shaping lower peaks and troughs. Medium- as well as short-term trends are down for the NTPC. Last month, the stock tumbled breaking its significant support at ₹130 that was providing base for the stock for almost two months.
The stock is trading well below its 50- and 200-day moving averages. Nevertheless, the stock is trading above a key long-term support at ₹100. You can hold the stock with a stop-loss at ₹95.
A decisive fall below ₹100 will drag the stock down to ₹80 in the long-term. On the other hand, the stock needs to rally above ₹135 to alter the short term downtrend and take it upwards to ₹147 or ₹160 in the medium-term.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.